GlassScriptPhysician profile
Nu Nwe Tun
NPI 1942685466
$2,912.27
in general payments reported to CMS, 2019-2025
30 companies · $723 in 2025
The $723 reported for 2025 was more than what 85% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.64 · 2020: $252 · 2021: $12.57 · 2022: $185 · 2023: $921 · 2024: $742 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,386.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $357.45 | 2019-2025 | Jardiance |
| Abbvie INC. | $343.20 | 2022-2025 | Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $270.22 | 2019-2025 | Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $231.01 | 2023-2025 | |
| Novo Nordisk INC | $229.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $181.31 | 2022-2024 | |
| Amarin Pharma, INC. | $158.90 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $120.64 | 2023-2025 | Rexulti |
| Sanofi Pasteur INC. | $101.59 | 2023-2024 | |
| Lilly USA, LLC | $93.74 | 2020-2025 | Zepbound, Mounjaro |
| Sanofi-Aventis U.S. LLC | $92.96 | 2024-2025 | |
| Glaxosmithkline, LLC. | $84.44 | 2019-2024 | Shingrix, Arexvy |
| Xeris Pharmaceuticals, INC. | $67.23 | 2023-2025 | Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $66.99 | 2025 | Strensiq |
| Amgen INC. | $58.08 | 2024-2025 | Tepezza |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $49.36 | 2025 | Yorvipath |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.97 | 2025 | Relistor |
| Medtronic, INC. | $43.45 | 2021-2025 | Minimed 780g |
| Rhythm Pharmaceuticals, INC. | $39.19 | 2023 | Imcivree |
| Mylan Specialty L.P. | $37.35 | 2023-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $37.04 | 2023 | Gattex |
| Pfizer INC. | $35.37 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $33.48 | 2023 | Dupixent |
| Sumitomo Pharma America, INC. | $26.54 | 2025 | Gemtesa |
| Janssen Biotech, INC. | $23.08 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.90 | 2022 | |
| Astellas Pharma US INC | $18.69 | 2024 | Veozah |
| Kyowa Kirin, INC. | $16.26 | 2024 | Crysvita |
| Corcept Therapeutics | $16.00 | 2025 | Korlym |
| Lundbeck LLC | $13.52 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nu Nwe Tun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.